Search Within

Sydney X Lu

  1. "Survivorship Research"
Formats
  1. Meeting Abstract (23)
  2. Journal Article (10)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (34)
  2. Department of Medicine (34)
  3. Hematologic Malignancies, Division of (34)
  4. Hematology-Oncology Fellows (34)
  5. Survivorship Research (34)
  6. Sloan Kettering Institute Postdocs (33)

More Groups

People
  1. Alexander Lesokhin (31)
  2. Malin Hultcrantz (31)
  3. Neha Korde (31)
  4. Sham Mailankody (31)
  5. Hani Hassoun (30)
  6. Urvi Shah (30)

More People

Years
  1. 2025 (1)
  2. 2022 (8)
  3. 2021 (9)
  4. 2020 (9)
  5. 2019 (7)
Publications
  1. Blood (13)
  2. Clinical Lymphoma, Myeloma and Leukemia (4)
  3. Journal of Clinical Oncology (4)
  4. British Journal of Haematology (2)
  5. JAMA Oncology (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. American Society of Clinical Oncology (4)
  3. Elsevier Inc. (4)
  4. American Association for Cancer Research (2)
  5. American Medical Association (2)
  6. John Wiley & Sons (2)

More Publishers

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms
    Meeting Abstract

    Diamond, B.; Ziccheddu, B.; Boyle, E. M.; Maclachlan, K.; Taylor, J.; Watts, J. M.; Lu, S. X.; Coffey, D. G.; Bolli, N.; Papaemmanuil, E.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating serum-free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save